Company: STAA
Filing Date: 2025-12-17
Form Type: DFAN14A
Source: 0001213900-25-122870
Chunk: 3

Company: STAAR SURGICAL CO
Filing Date: 2025-12-17
Form: DFAN14A
Chunk 3
---
-delayed special meeting
of shareholders, we are confident our fellow shareholders will agree with us and reject this ill-advised transaction. Several large shareholders,
all three proxy advisory firms and at least one of the Company’s own directors have rightly expressed great skepticism about the
process, timing and price of the proposed deal.

Soon, it will be your task to govern STAAR in
the post-transaction era. We write to express our continued support for the Company, its products and its opportunity. For more than thirty
years, Broadwood has been an engaged and constructive shareholder, providing both equity and debt capital when needed, purchasing its
shares in the open market at times when they have been cheap, and advising when and as asked. We pledge to continue to do so when the
Company turns the page on this latest chapter. As we have said before, we believe the Company needs new leadership and several new directors
that have the confidence of shareholders. We would welcome the opportunity to work with other shareholders and you to ensure that transition
of key leaders occurs seamlessly.

As you also know, the only option available to
shareholders in the near term to improve the Board is to call a special meeting to remove some directors, since your bylaws do not allow
shareholders to do anything else. We cannot, for example, put forward director candidates for shareholders to elect until the next Annual
Meeting, whenever that may be. But the best way to turn the page would be for the Board to work with shareholders to immediately make
the changes that are needed to restore its credibility and alignment with shareholders.

After all, we want nothing more than for STAAR
to succeed and for all shareholders to benefit from that success. And, we are confident that STAAR will succeed if it remains an
independent Company in the near term, even if it is later acquired through a truly fair and open auction process.

With inventories normalizing in China and new
products being launched, our analysis and financial models indicate that there is a clear path to a $50 per share stock price next year,
even without a return to normal growth rates in the global refractive surgery market. We also are confident that the refractive market’s
return to normal growth is a matter of when, not if. We should all keep in mind that, just a few years ago, when this business was significantly
smaller, STAAR’s stock price reached $160 per share. Now, the management team is projecting strong growth, great margins, substantial
oper